Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Venaxis, Inc.ex99x1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported) January 15, 2013
 
   
Venaxis, Inc.
   
   
(Exact name of Registrant as specified in its charter)
 
 
 
 
Colorado
 
001-33675
 
84-1553387
(State or other jurisdiction of incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
1585 South Perry Street
Castle Rock, Colorado
 
80104
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code:
 
(303) 794-2000
 

(Former name or former address, if changed since last report.)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 

 
Item 8.01.  Other Events.
 
On January 15, 2013, Venaxis, Inc., (the “Company”) issued a press release titled — “Venaxis Initiates Patient Enrollment for APPY1 Pivotal Study.”  The press release is filed as Exhibit 99.1 to this Form 8-K.
 
Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibits
 
99.1 
Press Release of Venaxis, Inc. titled “Venaxis Initiates Patient Enrollment for APPY1 Pivotal Study,” issued January 15, 2013.
 

 
 
 
 
 

 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

         
 
Venaxis, Inc.
(Registrant)
 
 
January 15, 2013
By:  
 /s/ Jeffrey G. McGonegal  
 
   
Name:  
Jeffrey G. McGonegal
 
   
Title:  
Chief Financial Officer